CN111417625A - 用于治疗过度增生性疾病的咖啡酸衍生物 - Google Patents

用于治疗过度增生性疾病的咖啡酸衍生物 Download PDF

Info

Publication number
CN111417625A
CN111417625A CN201880077894.0A CN201880077894A CN111417625A CN 111417625 A CN111417625 A CN 111417625A CN 201880077894 A CN201880077894 A CN 201880077894A CN 111417625 A CN111417625 A CN 111417625A
Authority
CN
China
Prior art keywords
compound
cancer
substituted
groups
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880077894.0A
Other languages
English (en)
Chinese (zh)
Inventor
W·普里贝
S·斯科拉
I·福克特
R·齐林斯基
A·贾古玛
R·维努戈帕尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN111417625A publication Critical patent/CN111417625A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201880077894.0A 2017-11-10 2018-11-09 用于治疗过度增生性疾病的咖啡酸衍生物 Pending CN111417625A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584591P 2017-11-10 2017-11-10
US62/584591 2017-11-10
PCT/US2018/059975 WO2019094689A1 (en) 2017-11-10 2018-11-09 Caffeic acid derivatives for treating hyperproliferative diseases

Publications (1)

Publication Number Publication Date
CN111417625A true CN111417625A (zh) 2020-07-14

Family

ID=64664389

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880077894.0A Pending CN111417625A (zh) 2017-11-10 2018-11-09 用于治疗过度增生性疾病的咖啡酸衍生物

Country Status (14)

Country Link
US (1) US10703721B2 (https=)
EP (1) EP3707125A1 (https=)
JP (1) JP7428642B2 (https=)
KR (1) KR20200085815A (https=)
CN (1) CN111417625A (https=)
AU (1) AU2018366270B2 (https=)
BR (1) BR112020009219A2 (https=)
CA (1) CA3081975A1 (https=)
EA (1) EA202091164A1 (https=)
MX (1) MX2020004871A (https=)
SG (1) SG11202004230XA (https=)
TW (1) TWI846678B (https=)
UA (1) UA126821C2 (https=)
WO (1) WO2019094689A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12539503B2 (en) 2022-08-03 2026-02-03 The University Of Toledo Environmentally friendly polymeric sorbent material for the extraction and determination of rare earth elements, thorium, and uranium

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102143947A (zh) * 2008-07-08 2011-08-03 得克萨斯系统大学评议会 增殖和信号转导及转录激活蛋白激活的新抑制剂
CN102603565A (zh) * 2003-12-11 2012-07-25 得克萨斯州大学系统董事会 治疗细胞增殖疾病的化合物
CN103261169A (zh) * 2010-09-24 2013-08-21 密歇根大学董事会 脱泛素酶抑制剂及其应用方法
WO2015187427A1 (en) * 2014-06-02 2015-12-10 Pharmakea, Inc. Deubiquitinase inhibitors
CN105705504A (zh) * 2013-10-10 2016-06-22 密歇根大学董事会 去泛素化酶抑制剂及其使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119069A0 (en) 1996-08-14 1996-11-14 Mor Research Applic Ltd Pharmaceutical composition comprising tyrphostins
WO2003068157A2 (en) 2002-02-11 2003-08-21 The Brigham And Women's Hospital, Inc. Kinase inhibitors and methods of use thereof
BRPI0709916B8 (pt) 2006-03-31 2021-05-25 Univ Texas drogas anticâncer associadas ao ácido caféico biodisponível por via oral e uso das referidas drogas
WO2008005954A2 (en) 2006-06-30 2008-01-10 The Board Of Regents Of The University Of Texas System Tryphostin-analogs for the treatment of cell proliferative diseases
US20130129675A1 (en) 2009-12-04 2013-05-23 Board Of Regents, The University Of Texas System Interferon therapies in combination with blockade of stat3 activation
WO2015183987A1 (en) 2014-05-27 2015-12-03 Pharmakea, Inc. Compositions and methods of delivery of deubiquitinase inhibitors

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102603565A (zh) * 2003-12-11 2012-07-25 得克萨斯州大学系统董事会 治疗细胞增殖疾病的化合物
CN102143947A (zh) * 2008-07-08 2011-08-03 得克萨斯系统大学评议会 增殖和信号转导及转录激活蛋白激活的新抑制剂
CN103261169A (zh) * 2010-09-24 2013-08-21 密歇根大学董事会 脱泛素酶抑制剂及其应用方法
CN105705504A (zh) * 2013-10-10 2016-06-22 密歇根大学董事会 去泛素化酶抑制剂及其使用方法
WO2015187427A1 (en) * 2014-06-02 2015-12-10 Pharmakea, Inc. Deubiquitinase inhibitors

Also Published As

Publication number Publication date
WO2019094689A1 (en) 2019-05-16
MX2020004871A (es) 2020-08-06
EP3707125A1 (en) 2020-09-16
JP2021502374A (ja) 2021-01-28
TWI846678B (zh) 2024-07-01
UA126821C2 (uk) 2023-02-08
AU2018366270A1 (en) 2020-05-21
KR20200085815A (ko) 2020-07-15
CA3081975A1 (en) 2019-05-16
AU2018366270B2 (en) 2023-04-20
TW201922707A (zh) 2019-06-16
US20190177276A1 (en) 2019-06-13
JP7428642B2 (ja) 2024-02-06
SG11202004230XA (en) 2020-06-29
BR112020009219A2 (pt) 2020-10-20
EA202091164A1 (ru) 2020-08-03
US10703721B2 (en) 2020-07-07

Similar Documents

Publication Publication Date Title
JP7105851B2 (ja) Ｈｓｐ９０阻害物質およびｈｓｐ７０誘導物質としての修飾エーテル基を有するビフェニルアミド
CN109820853B (zh) 取代的杂环化合物在制备治疗癌症药物中的用途
US10689344B2 (en) Biphenylamide derivative Hsp90 inhibitors
TW200815398A (en) A novel indazole derivative having spirocyclic structure in the side chain
CN112672997A (zh) 哒嗪酮衍生物
JP5649652B2 (ja) 置換ヒドラジド類化合物及びその応用
WO2013013614A1 (zh) 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
CN104230952B (zh) 含有嘧啶骨架的化合物及其制备方法和用途
CN115703761A (zh) 作为wwp1抑制剂的化合物及其应用
KR20160027068A (ko) 1,7-나프티리딘 유도체
CN111417625A (zh) 用于治疗过度增生性疾病的咖啡酸衍生物
WO2017223514A1 (en) Lxr inverse agonists for treatment of cancer
TWI722106B (zh) 具有抗癌活性之嘌呤化合物
CN113105409A (zh) 2-(羟基苄基)苯并[d]异噻唑酮类化合物、其制备方法和用途
WO2020206118A1 (en) Remodilins to prevent or treat cancer metastasis, glaucoma, and hypoxia
CN118994161B (zh) 一种(s)-2-(4-(4-甲基-1-哌嗪基)苯胺基)-8-苯胺基-9-(3-哌啶基)-9h-嘌呤及其应用
CA3072698A1 (en) Sulfonamide derivatives as stat3 inhibitors for the treatment of proliferative diseases
CN108117551A (zh) 取代(1H-吡唑[3,4-b]吡啶)脲类化合物及其抗肿瘤用途
CN120192295A (zh) 一种芳基丙胺类衍生物及其应用
KR20230118883A (ko) Enpp1 억제제로서의 이미다졸 화합물
BR112016029672B1 (pt) Composto bifenil amida com grupos éter modificados como inibidores de hsp90 e indutores de hsp70, composição farmacêutica que compreende o dito composto, bem como uso terapêutico do mesmo

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200714

WD01 Invention patent application deemed withdrawn after publication